WeVote
Log In

Bill

Bill

S 4676

Adds xylazine to the depressants designated as controlled substances

2025 Regular Session Introduced by Jake Ashby and 13 co-sponsors

Bill S 4676 classifies xylazine as a controlled substance, regulating its use to combat misuse and protect public health, impacting veterinary practices and law enforcement.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · S 4676

Summary of Bill S 4676

Bill Overview

  • Bill Number: S 4676
  • Title: Adds xylazine to the depressants designated as controlled substances
  • Status: Referred to Health
  • Introduced On: February 11, 2025
  • Classification: Legislative Bill

Purpose and Intent

The primary purpose of Bill S 4676 is to classify xylazine, a veterinary tranquilizer, as a controlled substance under the category of depressants. This classification aims to regulate the use, distribution, and possession of xylazine, which has been increasingly associated with illicit drug use and public health concerns.

Key Provisions

  • Inclusion of Xylazine: The bill specifically adds xylazine to the list of substances classified as depressants. This means that:
    • Regulation: The manufacture, distribution, and possession of xylazine will be subject to strict regulatory controls.
    • Legal Consequences: Violations related to the unauthorized use or distribution of xylazine may lead to criminal charges, similar to those for other controlled substances.

Impact

  • Public Health: By regulating xylazine, the bill aims to mitigate the risks associated with its misuse, particularly in combination with other substances like opioids, which can lead to severe health complications and fatalities.
  • Veterinary Practices: The bill may impact veterinary practices that use xylazine for animal sedation, requiring them to comply with new regulations regarding its use and distribution.
  • Law Enforcement: The classification will empower law enforcement agencies to take action against illegal trafficking and misuse of xylazine.

Procedural Aspects

  • Current Status: As of February 11, 2025, the bill has been referred to the Health Committee for further consideration.
  • Related Legislation:
    • S 7763: A related bill from the prior session that may address similar issues regarding controlled substances.
    • A 5099: A companion bill in the Assembly that aligns with the objectives of S 4676.

Conclusion

Bill S 4676 represents a legislative effort to address the growing concerns surrounding the misuse of xylazine by regulating it as a controlled substance. The bill's passage could have significant implications for public health, veterinary practices, and law enforcement efforts in combating substance abuse. Further discussions and evaluations by the Health Committee will determine the bill's future trajectory.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.